Heatbud logo
TOP CHARTS
BLOG POSTS
SEARCH
HELP CENTER
LOGIN / SIGNUP
Market ResearchNest Visit zone home page
Open Zone
Favorite
< Previous Post
> Next Post
Create a Post
Create a Zone
MY ZONES
Login to favorite zones.
TOP ZONES+
  • Business
       
  • Market ResearchNest
       
  • MarketResearch
       
  • Trendy Women Tops That Will Help You To Improve
       
  • eMarketOrg.com
       
  • Research Trades Business Report
       
  • My Zone
       
  • Car Accessories
       
  • Politics
       
  • Health
       
  • College
       
  • Global QYResearch
       
  • Yada Yada Yada
       
  • Singing Bowls
       
  • Market Research Report
       
  • Provue
       
  • AlgoroReports
       
  • Chemical
       
  • Fashion Stylist
       
  • Electronics Devices
       
Join the Social Blogging revolution!
C-C Chemokine Receptor Type 5 Therapeutics H2 Pipeline Industry Review 2017
by
Share Blog Post by URL Like Heatbud on Facebook
UNIQUE VIEWS   +   UP VOTES Vote Up   -   DOWN VOTES Vote Down   +   COMMENTS Comments   =   HEAT INDEX What is Heat Index?

MarketResearchNest.com adds “C-X-C Chemokine Receptor Type 2 (CDw128b Or GRO/MGSA Receptor Or High Affinity Interleukin 8 Receptor B Or IL8 Receptor Type 2 Or CD182 Or CXCR2) - Pipeline Review, H2 2017” new report to its research database. The report spread across in 59 pages with table and figures in it.

 

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Cardiovascular, Central Nervous System, Infectious Disease and Metabolic Disorders which include indications Inflammation, Metastatic Breast Cancer, Asthma, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Pain, Liver Transplant Rejection, Lung Infections, Lung Transplant Rejection, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Post-Operative Pain, Prostate Cancer, Pulmonary Inflammation, Respiratory Syncytial Virus (RSV) Infections, Solid Tumor, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections. 

The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2017, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.             

Browse full table of contents and data tables at

https://www.marketresearchnest.com/c-x-c-chemokine-receptor-type-2-cdw128b-or-gro-mgsa-receptor-or-high-affinity-interleukin-8-receptor-b-or-il8-receptor-type-2-or-cd182-or-cxcr2---pipeline-review-h2-2017.html     

Featured News & Press Releases
Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions 48
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells 49
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer 49
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells 50
Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation 51
Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true 52
Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium 53
Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin 55
Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress 56
Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation 56

Companies mentioned in this report includes:

AstraZeneca Plc,ChemoCentryx Inc,Dompe Farmaceutici SpA,GlaxoSmithKline Plc,Novartis AG,Syntrix Biosystems Inc

 

Order a Premium Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=253136

 

Scope
- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
- The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities 
- The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics


Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective - Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 

Enquiry before buying at https://www.marketresearchnest.com/enquirybuy.php?reportid=253136

               

About Us:                           

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

                                                   

Contact Us

Mr. Jeet Jain

Sales Manager

sales@marketresearchnest.com

+1-240-284-8070

Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Comments:
0 blogger(s) are following this post, but not you. Follow?
No comments yet.
 
Post a Comment:

 
Related Posts: